8 completed, 5 recruiting, 2 terminated, 1 active not recruiting. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 8, Recruiting 5, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-09-22 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 279 | 2025-05-20 | 2026-03-02 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 787 | 2025-05-20 | 2026-03-02 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure Acalabrutinib, Investigator's choice of treatment - Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | Phase 4 | Recruiting | AstraZeneca | 60 | 2025-02-04 | 2026-09-24 |
| Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Venetoclax - Chronic Lymphocytic Leukemia | Phase 4 | Not yet recruiting | Paolo Ghia | 30 | 2023-11-01 | 2023-10-03 |
| Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma Acalabrutinib capsule - Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma | Phase 4 | Completed | AstraZeneca | 103 | 2021-07-14 | 2024-11-22 |
| A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Ibrutinib 420 mg, Ibrutinib 560 mg - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell | Phase 4 | Completed | Johnson & Johnson Private Limited | 75 | 2019-06-26 | 2025-05-25 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin | Phase 4 | Active not recruiting | Pharmacyclics Switzerland GmbH | 297 | 2017-05-22 | 2025-10-30 |
| A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Cyclophosphamide, Fludarabine, Rituximab - Lymphocytic Leukemia, Chronic | Phase 4 | Terminated | Hoffmann-La Roche | 89 | 2011-06-17 | 2018-03-20 |
| A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Chlorambucil, Cyclophosphamide, Fludarabine - Lymphocytic Leukemia, Chronic | Phase 4 | Terminated | Hoffmann-La Roche | 26 | 2011-04-27 | 2019-03-14 |
| Antiviral Treatment of Chronic Lymphocytic Leukemia Valganciclovir - Chronic Lymphocytic Leukemia | Phase 4 | Completed | Medical University of Vienna | 20 | 2010-12-01 | 2015-07-21 |
| A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) bendamustine, chlorambucil, rituximab [MabThera/Rituxan] - Lymphocytic Leukemia, Chronic | Phase 4 | Completed | Hoffmann-La Roche | 357 | 2010-03-01 | 2015-06-25 |
| The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Pneumococcal polysaccharide vaccine (PPV) - Chronic Lymphocytic Leukemia (CLL) | Phase 4 | Completed | Tampere University Hospital | 32 | 2009-06-01 | 2014-02-19 |
| Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Ofatumumab - Leukaemia, Lymphocytic, Chronic | Phase 4 | Completed | GlaxoSmithKline | 29 | 2009-01-01 | 2014-05-14 |
| Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Nipent, Cytoxan, Rituxan - Chronic Lymphocytic Leukemia | Phase 4 | Unknown | East Valley Hematology and Oncology Medical Group | 180 | 2003-01-01 | 2005-08-18 |
| A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Fludarabine Phosphate (Fludara) - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 4 | Completed | Genzyme, a Sanofi Company | 10 | 2000-11-01 | 2013-12-04 |
| Bone Marrow Transplantation in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, cyclophosphamide - Anemia, Graft Versus Host Disease | Phase 4 | Completed | University of Maryland, Baltimore | 45 | 1998-09-01 | 2019-10-17 |
Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Mantle-Cell (3) · Graft vs Host Disease (2) · Leukemia (2) · Lymphoma (2) · Neoplasms, Plasma Cell (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Anemia (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Leukemia, Lymphoid (18) · Lymphoproliferative Disorders (18) · Neoplasms by Histologic Type (18) · Lymphatic Diseases (17) · Neoplasms (17) · Chronic Disease (16) · Disease Attributes (16) · Leukemia (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16)
Rituximab (5) · Cyclophosphamide (4) · pirtobrutinib (3) · Chlorambucil (2) · acalabrutinib (2) · fludarabine (2) · ibrutinib (2) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Biopsy, Needle (1) · Everolimus (1) · Filgrastim (1) · Pentostatin (1) · Pneumococcal Vaccines (1) · Prednisone (1)
Eli Lilly and Company (3) · Hoffmann-La Roche (3) · AstraZeneca (2) · Dana-Farber Cancer Institute (1) · East Valley Hematology and Oncology Medical Group (1) · Genzyme, a Sanofi Company (1) · GlaxoSmithKline (1) · Johnson & Johnson Private Limited (1) · Medical University of Vienna (1) · Paolo Ghia (1) · Pharmacyclics Switzerland GmbH (1) · Tampere University Hospital (1) · University of Maryland, Baltimore (1)
United States (8) · United Kingdom (6) · France (5) · Italy (5) · Poland (5) · Australia (4) · Spain (4) · Czechia (3) · Japan (3) · Russia (3) · South Korea (3) · Sweden (3) · Austria (2) · Canada (2) · Finland (2)
Ann Silk, MD (1) · Barry R. Meisenberg, MD (1) · Christoph Steininger, MD (1) · Kevin Wu (1) · Raul Mena, MD (1)
PMID 26377300, PMID 29420116, PMID 42787222
2009 (2), 2016 (1)